Browsing Tag
CSL Limited
7 posts
ASX healthcare sector falls harder than the broader market as rate shock and Middle East war pressure high-multiple stocks
ASX healthcare stocks fell 2.47% on 19 March, lagging every other defensive sector. Here's what's driving CSL, Pro Medicus and Cochlear lower. Read more.
CSL (ASX:CSL) breaks ground on $1.5bn Kankakee plasma plant expansion, betting patented Horizon 2 technology can widen its immunoglobulin lead
CSL (ASX:CSL) breaks ground on a $1.5B Kankakee plasma plant expansion using patented Horizon 2 yield tech. Read the full strategic analysis.
Five-year durability data show Hemgenix is transforming haemophilia B care with a single dose
Five‑year results show Hemgenix delivers long‑lasting bleed protection and stable clotting factor levels for haemophilia B patients. Read more on the breakthrough here.
CSL Seqirus data show cell-based flu vaccine provides 20% stronger protection against lab-confirmed influenza
Find out how CSL Seqirus’s real-world data reveal a 20% protection boost for its cell-based flu vaccine over traditional egg-based shots.
Nyrada Inc (ASX: NYR) stock draws fresh attention as investors eye trial milestones in 2025
Nyrada Inc (ASX: NYR) stock is moving on higher volumes as trial milestones near. Find out why investors are watching this biotech in 2025.
FILSPARI secures full European approval: A major breakthrough for IgA nephropathy patients
Find out how FILSPARI’s full EU approval marks a major step for IgA nephropathy treatment and strengthens CSL Vifor and Travere Therapeutics’ rare disease focus.
CSL Limited’s AEGIS-II trial of CSL112 fails to meet primary endpoint in heart attack patients
CSL Limited (ASX:CSL; USOTC:CSLLY), a renowned global biotechnology leader, disclosed the top-line outcomes from its eagerly anticipated Phase…